vs
Side-by-side financial comparison of Instil Bio, Inc. (TIL) and Zhibao Technology Inc. (ZBAO). Click either name above to swap in a different company.
Zhibao Technology Inc. is the larger business by last-quarter revenue ($4.1M vs $2.2M, roughly 1.8× Instil Bio, Inc.). Zhibao Technology Inc. runs the higher net margin — -2.1% vs -365.3%, a 363.2% gap on every dollar of revenue. On growth, Instil Bio, Inc. posted the faster year-over-year revenue change (-19.2% vs -79.7%).
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
TIL vs ZBAO — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.2M | $4.1M |
| Net Profit | $-8.2M | $-85.5K |
| Gross Margin | — | 34.8% |
| Operating Margin | -426.3% | 2.2% |
| Net Margin | -365.3% | -2.1% |
| Revenue YoY | -19.2% | -79.7% |
| Net Profit YoY | 31.1% | 3.2% |
| EPS (diluted) | $-1.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2M | $4.1M | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $2.8M | $20.1M | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
| Q4 25 | $-8.2M | $-85.5K | ||
| Q3 25 | $-13.6M | — | ||
| Q2 25 | $-21.4M | — | ||
| Q1 25 | $-28.2M | — | ||
| Q4 24 | $-11.9M | $-88.3K | ||
| Q3 24 | $-23.0M | — | ||
| Q2 24 | $-14.9M | — | ||
| Q1 24 | $-24.3M | — |
| Q4 25 | — | 34.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -426.3% | 2.2% | ||
| Q3 25 | -670.0% | — | ||
| Q2 25 | -1045.5% | — | ||
| Q1 25 | -1363.2% | — | ||
| Q4 24 | -426.1% | 2.6% | ||
| Q3 24 | -1582.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -365.3% | -2.1% | ||
| Q3 25 | -606.0% | — | ||
| Q2 25 | -954.2% | — | ||
| Q1 25 | -1257.8% | — | ||
| Q4 24 | -428.8% | -0.4% | ||
| Q3 24 | -1541.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-1.13 | — | ||
| Q3 25 | $-2.01 | — | ||
| Q2 25 | $-3.24 | — | ||
| Q1 25 | $-4.32 | — | ||
| Q4 24 | $-1.82 | $0.00 | ||
| Q3 24 | $-3.54 | — | ||
| Q2 24 | $-2.29 | — | ||
| Q1 24 | $-3.74 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.6M | $3.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $113.9M | $6.8M |
| Total Assets | $203.5M | $39.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.6M | $3.8M | ||
| Q3 25 | $5.8M | — | ||
| Q2 25 | $7.7M | — | ||
| Q1 25 | $15.4M | — | ||
| Q4 24 | $8.8M | $3.9M | ||
| Q3 24 | $6.7M | — | ||
| Q2 24 | $6.8M | — | ||
| Q1 24 | $5.5M | — |
| Q4 25 | $113.9M | $6.8M | ||
| Q3 25 | $120.4M | — | ||
| Q2 25 | $131.7M | — | ||
| Q1 25 | $144.9M | — | ||
| Q4 24 | $169.4M | $10.0M | ||
| Q3 24 | $176.3M | — | ||
| Q2 24 | $195.0M | — | ||
| Q1 24 | $205.8M | — |
| Q4 25 | $203.5M | $39.1M | ||
| Q3 25 | $211.8M | — | ||
| Q2 25 | $231.0M | — | ||
| Q1 25 | $237.4M | — | ||
| Q4 24 | $263.6M | $43.2M | ||
| Q3 24 | $272.6M | — | ||
| Q2 24 | $294.3M | — | ||
| Q1 24 | $306.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.1M | $-241.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.1M | $-241.5K | ||
| Q3 25 | $-10.6M | — | ||
| Q2 25 | $-14.8M | — | ||
| Q1 25 | $-4.2M | — | ||
| Q4 24 | $-10.6M | $10.2M | ||
| Q3 24 | $-20.1M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $-14.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
